Peginterferon alfa-2b (Merck Sharp & Dohme)

聚乙二醇干扰素α-2b（默沙东）

Report date: 2023/05/15 17:46:01

Base Information

Drug NamePeginterferon alfa-2b (Merck Sharp & Dohme)
Drug Alias Name培干扰素 α-2bPEG interferon-alpha-2bpeginterferonum alfa-2bInterferon-alpha-2b macrogolPegylated interferon-alpha-2b +[29] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsSkin MelanomaSolid tumoursHypoxia +[32] 
Global Approved IndicationsMelanomaHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryEU
Original Approved Date2000/05/24
Country/TerritoryUnited StatesPuerto RicoFrance +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesSp EuropeMerck Sharp & Dohme CorpSchering Ag
Inactive CompaniesNewlink Genetics CoNational Institutes Of Health Clinical Center (Cc)Schering-Plough +[12] 
Active IndicationsMelanomaHepatitis C
Inactive IndicationsSkin MelanomaSolid tumoursHypoxia +[30] 

Other Information

ATC CodeL03AB10
Related LinksWikipediaDrugBankKEGG